We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 35.33 | 39.33 | 41.45 | 56.68 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 64.02 | 53.15 | 67.61 | 81.89 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 451 | 486 | 498 | 542 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.16 | 9.25 | 9.89 | 10.76 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4,129.19 | 4,497.83 | 4,924.27 | 5,833.98 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 93.26% | 93.03% | 93.49% | 94.38% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (94.14) | (115.58) | (8.00) | 204.32 | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.28%) | (2.57%) | (0.16%) | 3.50% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.93) | (30.30) | 88.35 | 261.52 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,147.21 | 1,355.27 | 1,229.04 | 1,372.22 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.33 | 11.19 | 11.96 | 12.82 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | (0.12) | (0.10) | 0.20 | 0.55 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.80 | 2.79 | 3.23 | 3.62 | ‡‡‡‡ | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.56) | (0.65) | (0.68) | (0.80) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.25 | 2.14 | 2.55 | 2.82 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.58 | 23.75 | 26.30 | 27.66 | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 399.55 | 401.81 | 411.77 | 455.08 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 309.95 | 140.69 | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.39 | 4.52 | 4.92 | 6.04 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.77 | 2.13 | 2.24 | 2.80 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.55 | 7.41 | 7.49 | 8.15 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 34.71 | 38.74 | 35.21 | 37.04 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,120.16 | 1,119.87 | 1,329.63 | 1,646.73 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (222.13) | (259.41) | (281.61) | (363.86) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 898.03 | 860.46 | 1,048.01 | 1,282.86 | ‡‡‡‡‡ | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (434.41) | (567.57) | (193.55) | (453.87) | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13,211.78 | 13,490.90 | 13,522.55 | 13,011.02 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13,041.04 | 12,927.44 | 12,565.32 | 12,224.88 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10,221.68 | 9,544.41 | 10,829.60 | 12,585.81 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.19%) | (0.17%) | 0.32% | 0.93% | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.35% | 1.10% | 1.82% | 2.16% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.45%) | (0.41%) | 0.80% | 2.15% | ‡‡‡‡‡ | — | — |
ROE
|
Ventas, Inc. (VTR) Latest News
15 Sep
Jefferies launches healthcare REIT coverage favoring senior housing, with positive implications for Ventas Inc. (VTR) exposure in the sector. Sector-favorable analyst coverage may lift short-term sentiment and valuation for Ventas senior housing assets.
14 Aug
RBC reports Ventas earnings growth supported by strong senior housing trends. RBC positive view on senior housing trends points to moderate boost for Ventas earnings outlook and stock sentiment.
7 Aug
Ventas, Inc. (VTR) held its Q2 2026 earnings call, covering financial results, operational updates, and forward outlook for the REIT. Q2 2026 earnings call delivers performance metrics and guidance that typically drive material shifts in investor views and stock trajectory.
1 Aug
Ventas Q2 earnings call highlighted financial results, operational updates and management guidance on future performance. Q2 earnings details and guidance typically drive moderate short-term investor reaction without altering long-term trajectory.
30 Jul
Ventas Inc posted record NOI growth for Q2 2026 and raised its guidance. Record NOI growth and raised guidance point to strong results that can materially lift future performance and investor sentiment.
Ventas Q2 FFO and revenues exceeded estimates on strong senior housing operating portfolio growth. Q2 earnings beat with SHOP growth supports short-term positive market reaction but does not signal major strategic shifts.
29 Jul
Ventas (VTR) reported Q2 earnings with key financial metrics compared to Wall Street estimates. Q2 earnings metric comparisons indicate company financial performance versus expectations.
Ventas, Inc. reported its second quarter 2026 financial results. Quarterly results update financial performance and can shift near-term investor sentiment without altering long-term strategy.
24 Jul
Analysts upgraded earnings outlook for Ventas (VTR), shifting its investment story to reflect improved financial expectations. Upgraded earnings forecasts can lift near-term investor sentiment and share price without altering long-term fundamentals.
23 Jul
Ventas (VTR) approaches earnings season with focus on REIT performance, healthcare property trends, occupancy rates, and interest rate effects on real estate valuations and investor outlook. Earnings season expectations typically produce moderate short-term shifts in VTR stock sentiment without altering long-term REIT fundamentals.
8 Jun
Ventas updated its outlook and reaffirmed the dividend, leading to a valuation reassessment of the company. Updated outlook and reaffirmed dividend can moderately shift investor sentiment toward Ventas financial trajectory.
7 May
JPMorgan's stake in Ventas underscores valuation debates for the senior housing REIT amid positive sector outlook. JPMorgan's stake signals major investor confidence, likely lifting Ventas' valuation and market sentiment in growing senior housing demand.
29 Apr
Ventas Inc. (VTR) reported strong NOI growth and increased investments in its Q1 2026 earnings call, highlighting robust performance across segments. Strong NOI growth and increased investments indicate significant positive momentum for financial performance and expansion.
Ventas, Inc. (VTR) released Q1 earnings call highlights detailing financial results, operational updates, portfolio performance, and forward guidance amid healthcare real estate market dynamics. Q1 earnings highlights provide moderately noticeable insights into financial health and strategy, influencing short-term market sentiment without fundamental shifts.
28 Apr
Ventas, Inc. (VTR) released its Q1 2026 earnings call transcript, covering quarterly financial results, operational updates, and management's outlook. Q1 2026 earnings transcript details financial performance, guidance, and strategy, poised to significantly sway investor sentiment and stock trajectory.
Ventas Inc. (VTR) Q1 FFO and revenues beat analyst estimates, driven by strong SHOP segment results. Q1 FFO and revenue beats from robust SHOP performance enhance financial outlook and investor confidence, significantly influencing stock trajectory.
Ventas, Inc. summarized Q1 2026 earnings call, highlighting financial results, operational performance in seniors housing and healthcare properties, revenue growth, FFO guidance, and strategic investments amid market challenges. Q1 earnings summaries detail financial metrics and guidance that significantly influence Ventas' trajectory and investor sentiment.
27 Apr
Ventas, Inc. (VTR) reported first quarter 2026 results, highlighting financial performance across its healthcare real estate portfolio. Quarterly earnings reports drive significant shifts in investor sentiment and stock valuation for REITs like Ventas.
Key metrics from Ventas (VTR) Q1 earnings provide insights into the company's financial performance and operational health. Q1 earnings metrics affect financial performance and investor sentiment but represent routine quarterly reporting.
Ventas (VTR) reported Q1 FFO and revenues surpassing analyst estimates. Q1 FFO and revenue beats positively affect financial performance and market sentiment with moderate influence.
24 Apr
Ventas, Inc. (VTR) sees upbeat earnings revisions and improved revenue outlook, positively transforming its investment story. Upbeat earnings revisions and revenue outlook signal major positive shifts in VTR's financial trajectory and investor sentiment.
Ventas, Inc. (VTR) Q1 earnings preview highlights expected performance amid operational challenges, portfolio strength, and market conditions in healthcare real estate. Q1 earnings preview could noticeably affect financial results expectations and short-term investor sentiment.
21 Apr
Ventas (VTR) enters earnings season with analysts forecasting normalized FFO growth, improved senior housing occupancy, and strong SHOP performance amid rising demand from aging demographics, positioning the REIT for potential upside if results exceed expectations. Earnings previews like FFO projections and occupancy trends moderately influence Ventas' near-term financial outlook and stock sentiment.
8 Apr
Ventas Inc. (VTR) faces upcoming earnings report with analysts expecting scrutiny on senior housing occupancy, rental rate growth, and divestiture impacts amid healthcare real estate challenges. Earnings previews shape investor expectations for financial performance and operational metrics in healthcare REIT sector.
3 Apr
Ventas (VTR) fresh Q1 results and expanded 2026 investment pipeline may alter the bull case outlook. Q1 results and expanded 2026 investment pipeline indicate significant strategic growth for Ventas.
2 Apr
Ventas, Inc. (VTR) released its 2025 annual results, detailing financial performance across its healthcare real estate portfolio. Annual results reveal key financial metrics that significantly shape investor expectations and Ventas' market trajectory.
20 Mar
Ventas (VTR) capitalizes on the 'Gray Wave' of aging population growth, fueling demand for its senior housing and healthcare properties, while offering a strong 4%+ dividend yield that attracts income investors; analysts remain bullish on long-term performance. Aging demographics boost demand for senior living assets, supporting revenue growth but tempered by broader market and operational factors.
16 Mar
Ventas, Inc. (VTR), a REIT akin to Welltower, recently raised its dividend, positioning it as a compelling investment option. Ventas's dividend hike signals robust cash flow and financial health, likely driving positive investor sentiment and stock price appreciation.
12 Mar
Land & Buildings loads up National Affiliates Storage Trust with 1.3 million shares. Activist investor's accumulation of 1.3 million shares in the storage trust signals moderate potential for strategic pressure on Ventas.
26 Feb
Ventas Inc. announces finance leadership shift, with analysts suggesting it could narrow the company's persistent valuation gap by improving capital allocation and investor communication. Finance leadership change targets valuation discount through better strategy, moderately impacting financial performance and market sentiment.